<table id="t9" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Clinically Important Drug Interactions with VRAYLAR
</caption>
<col align="left" width="20.300%"></col>
<col align="left" width="79.700%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="bold">Strong CYP3A4 Inhibitors</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Concomitant use of VRAYLAR with a strong CYP3A4 inhibitor increases the exposures of cariprazine and its major active metabolite, didesmethylcariprazine (DDCAR), compared to use of VRAYLAR alone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s72">12.3</linkhtml>)].</content>
<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">If VRAYLAR is used with a strong CYP3A4 inhibitor, reduce VRAYLAR dosage <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s6">2.3</linkhtml>)]</content>.<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">itraconazole, ketoconazole
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">CYP3A4 is responsible for the formation and elimination of the active metabolites of cariprazine. The effect of CYP3A4 inducers on the exposure of VRAYLAR has not been evaluated, and the net effect is unclear <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s72">12.3</linkhtml>)].</content>
<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s4">2.1</linkhtml>, <linkhtml href="#s6">2.3</linkhtml>)]</content>.<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">rifampin, carbamazepine
</td>
</tr>
</tbody>
</table>